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doi:10.1
1550Objective: Our objective was to evaluate the natural history of moderate aortic stenosis in veterans—a unique
patient population with significant comorbidities.
Methods:We retrospectively reviewed the records of all patients who underwent echocardiography at a single
veterans affairs hospital during 2006. We identified consecutive patients who had moderate aortic stenosis as
indicated by a mean transaortic gradient of 25 to 40 mmHg, peak aortic jet velocity of 3 to 4 m/s, or aortic valve
area of 1.0 to 1.5 cm2. The primary end point was defined as survival without aortic valve replacement.
Results:Of the 104 patients (mean age, 74 10 years), 49% had diabetes, 21% had peripheral vascular disease,
21% were current smokers, 18% had chronic obstructive pulmonary disease, 60% had coronary artery disease,
89% had hypertension, and 31% had a body mass index of 30 kg/m2 or more. Mean ejection fraction was
49% 12%. During the mean follow-up period of 22 months (range, 1-67 months), 30% of patients underwent
aortic valve replacement—26% for symptomatic severe aortic stenosis and 4% concomitantly with coronary
artery bypass grafting as the primary indicated operation—and 61% died. Event-free survivals were 48%,
24%, and 15% at 1, 3, and 5 years, respectively.
Conclusions: Our cohort of military veteran patients had significant comorbidities. Event-free survival for such
patients who have moderate aortic stenosis is significantly lower than previously reported data suggest. Within
this unique group of patients, identifying factors that accelerate the progression of moderate aortic stenosis
would help surgeons select patients who may benefit from early aortic valve replacement for moderate aortic
stenosis. (J Thorac Cardiovasc Surg 2013;145:1550-3)Aortic stenosis (AS) is the most common type of valvular
heart disease in the developed world.1-3 Calcific AS is
a disease of the elderly, and as the population of the United
States continues to age, the increasing prevalence of this
type of AS represents a significant burden to patients and
a topic of intense interest and study for physicians.1-4
The majority of the existing literature on the natural his-
tory of AS focuses on ‘‘severe’’ disease, and aortic valve re-
placement (AVR) has clearly been established as the
standard of care in severe symptomatic AS.1,5 Among
patients with ‘‘hemodynamically significant’’ AS per
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The Journal of Thoracic and Cardiovascular Sursyncope, dyspnea, or other symptoms of heart failure have
been shown to have poorer survival and a greater risk of
sudden death without prompt surgical intervention than
patients with no symptoms.2,4,6-9
Asymptomatic moderate AS has been viewed as a rela-
tively benign condition, and current practice guidelines
recommend annual follow-up and surveillance echocardi-
ography every 1 to 2 years for patients with moderate
AS.1,4 Until recently, the natural history of moderate AS
has been poorly defined. However, recent studies suggest
that progression to severe disease can occur much more
rapidly than previously expected and that moderate AS
itself is associated with a substantial increase in mortality
from both cardiac and noncardiac causes.10-13 The studies
also identify characteristics (eg, moderate or severe aortic
valve calcification, concomitant coronary artery disease
[CAD]) that may put certain patients at risk for more
rapid progression of their AS.13-15 These findings call into
question the traditional paradigm of expectantly managing
patients with moderate AS, suggesting instead that many
patients require much closer follow-up and more aggressive
management than the present guidelines indicate.
To date, the natural history of moderate AS has not been
studied in the veteran population. Veterans represent
a unique patient population with significant risk factors,
including advanced age, concomitant CAD, and other
factors that have been shown to affect the progression ofgery c June 2013
Abbreviations and Acronyms
AS ¼ aortic stenosis
AVR ¼ aortic valve replacement
CAD ¼ coronary artery disease
MEDVAMC ¼ Michael E. DeBakey Veterans
Affairs Medical Center
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military veterans with moderate AS to better understand
the natural history and impact of this disease in this
unique group of patients.A
C
DPATIENTS AND METHODS
Patient Population
The study was granted waiver of consent and approved by the Institu-
tional Review Boards at the Michael E. DeBakey Veterans Affairs Medical
Center (MEDVAMC) and Baylor College of Medicine, Houston, Tex. We
retrospectively reviewed the medical records of all patients who underwent
Doppler echocardiography at theMEDVAMC from January 1, 2006, to De-
cember 31, 2006. Patients with moderate ASwere identified from the echo-
cardiographic database maintained by the Division of Cardiology. For the
purpose of our study, we defined moderate AS according to the current
American College of Cardiology/American Heart Association valvular
heart disease guidelines1: a peak aortic jet velocity of 3.0 to 4.0 m/s,
a mean transaortic valve pressure gradient of 25 to 40 mm Hg, or an aortic
valve area of 1.0 to 1.5 cm2. We excluded patients who had previous AVR,
incomplete echocardiographic data, or incomplete follow-up data.
We identified a total of 104 consecutive patients who met our prespeci-
fied criteria and conducted a detailed chart review, using the MEDVAMC
Computerized Patient Record System, to extract pertinent demographic,
echocardiographic, clinical, surgical, and follow-up data for each patient
(Table 1). The presence of diabetes mellitus, hypertension, CAD, chronic
obstructive pulmonary disease, and peripheral vascular disease as docu-
mented in the patients’ charts was recorded. The degree of aortic valve cal-
cification was not consistently documented in the echocardiographic
reports reviewed and was thus not included in our study.
Follow-up
Follow-up data were available on the Computerized Patient Record Sys-
tem for all patients, and follow-up began from the date of the first echocar-
diogram that indicated moderate AS. The primary end point of our study
was event-free survival, which was defined as freedom from death (from
any cause) and AVR until the end of the follow-up period in August 2011.
Statistical Analysis
Continuous variables were expressed as mean  standard deviation.
Probabilities of event-free survival at 1, 3, and 5 years were obtained by
Kaplan-Meier estimates (STATA version 11; StataCorp LP, College
Station, Tex).RESULTS
Event-Free Survival
During the mean follow-up period of 22 months (range,
1-67 months), 89 patients died (n ¼ 58), underwent AVR
(n ¼ 26), or underwent AVR and then died during the
follow-up period (n ¼ 5). Estimated event-free survivalThe Journal of Thoracic and Carwas 48% at 1 year, 24% at 3 years, and 15% at 5 years
(Figure 1).
Aortic Valve Replacement
Among the 31 patients who underwent AVR, severe
symptomatic AS was the primary surgical indication in
27; the remaining 4 patients underwent AVR concomitantly
with coronary artery bypass grafting because CAD was the
primary indication for surgery. Of the 27 patients who had
operations primarily for AVR, 15 had isolated AVR and
12 had concomitant coronary artery bypass grafting.
Death
Sixty-three patients died (from any cause) during the
study period: 58 of the deaths were considered primary
events and, as stated earlier, 5 deaths occurred after the pa-
tients underwent AVR. The available data did not allow us
to record specific causes of death or whether deaths were
of cardiac origin.
Patients With No Events
Of the 15 (14%) patients in whom no events were ob-
served, 3 had progressed to severe AS and 12 still had mod-
erate AS at the end of the follow-up period. At that time, 10
of these patients were recommended for monitoring with
surveillance echocardiography because of a lack of symp-
toms or disease progression. Two of the 15 patients were
deemed not to be surgical candidates, 2 were recommended
for AVR but wanted more time to decide, and 1 patient de-
clined any further workup or intervention for his AS.
DISCUSSION
The current standard of care for severe symptomatic AS
is AVR, because the existing data suggest that, otherwise,
patients have an average survival of only 2 to 3 years after
the onset of symptoms, and they have a high risk of sudden
death.1,2,16-19 Current guidelines for the management of
moderate AS recommend clinical follow-up yearly and
echocardiography every 1 to 2 years.1,4 However, the
results of our present study suggest that moderate AS may
not be as benign as previously reported10,13 and that
current practice guidelines may be inadequate, especially
for the military veteran population.
Previous studies of the natural history of moderate AS
have produced conflicting results. Specifically, Horstkotte
and Loogen17 and Turina and associates18 suggest that mod-
erate AS has a relatively benign course: Horstkotte and Lo-
ogen17 reported an average interval of 13.4 years from
diagnosis to aortic valve surgery, and Turina’s group18 re-
ported 100% and 80% survivals at 1 and 4 years after diag-
nosis, respectively. However, in a small study, Kennedy and
colleagues10 found that 14 of 66 patients died of causes at-
tributed to moderate AS within 35 months after diagnosis.
In addition, Otto’s group12 showed that event-free survivaldiovascular Surgery c Volume 145, Number 6 1551
TABLE 1. Patient characteristics (N ¼ 104)
Variable Value
Age (y) 74  10
Gender (male) 103 (99%)
Body mass index>30 kg/m2 32 (31%)
Current smoker 22 (21%)
Tobacco smoking history 66 (63%)
Diabetes mellitus 51 (49%)
Coronary artery disease 62 (60%)
Hypertension 93 (89%)
Chronic obstructive pulmonary disease 19 (18%)
Peripheral vascular disease 22 (21%)
Mean ejection fraction (%) 49  12
Peak aortic jet velocity (m/s) 3.2  0.6
Mean transaortic valve gradient (mm Hg) 25.2  9.7
Aortic valve area (cm2) 1.1  0.3
Data are presented as number (percentage) or as mean  standard deviation.
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Dat 2 years was 66%. Most recently, Rosenhek and associ-
ates13 reported 75% and 60% event-free survivals at 3
and 5 years, respectively. The same group also reported
that patients with mild or moderate AS had an overall mor-
tality that was 80% greater than that of age- and gender-
matched controls.
Our results suggest that not only is the natural history of
moderate AS in this veteran population not benign, but the
event-free survival is significantly lower than even what Ot-
to’s12 and Rosenhek’s groups13 had previously described.
Eighty-five percent of patients had an event within our
mean follow-up period of 22 months, and 61% of our pa-
tients died by the conclusion of our study, thus indicating
that mortality in patients with moderate AS is not
insignificant.
The body of literature on moderate AS also states that the
rate of disease progression varies significantly amongFIGURE 1. Kaplan-Meier event-free survival (events: aortic valve
replacement, n ¼ 31; death, n ¼ 58).
1552 The Journal of Thoracic and Cardiovascular Suraffected individuals.12,20 Some studies have attempted to
identify risk factors for more rapid progression.1,12-15,19,21
For example, studies have shown that severe disease
develops more rapidly in patients with senile calcific
stenosis than in those with rheumatic or congenital
AS.15,19 Other factors that have been associated with the
rapid progression of AS include advanced age,
concomitant CAD, and moderate to severe aortic valve
calcification.13,15,19,21 Given that calcific AS is associated
with aging, the association between advanced age and
more rapid progression is not surprising. Similarly, with
respect to its association with CAD, calcific AS was
previously understood to be a degenerative disease, but
more recent studies suggest that the pathophysiology of
calcific stenosis is in fact similar to that of
atherosclerosis.22,23 Thus, patients who have both AS and
CAD probably have more severe aortic valve calcification
than patients with AS alone. Finally, multiple studies have
associated increased mortality with any degree of
dystrophic calcification in either the aortic valve or the
aorta.24,25 In our cohort of veterans, patients tended to be
older (average age, 74 years) and to have significant
comorbidities. Of note, 60% of our patients had
concomitant CAD.
As our population ages and health care costs continue to
rise, the prevalence of AS will continue to increase, as well.
Additionally, because the MEDVAMC provides cardiac
care to veterans in a large geographic area (including south-
ern Texas, Louisiana, Oklahoma, Arkansas, Mississippi,
and western Florida), many of the military veterans who
are seen at our facility have to travel great distances. There-
fore, to aggressively follow up every patient with moderate
AS documented by echocardiography may be logistically
difficult. However, given that even within 1 year, event-
free survival is remarkably lower in this population than
in other studied populations and that all-cause mortality in
this group is high, we need to determine whether there is
a subset of patients with moderate AS and a high risk of
rapid disease progression who need to be followed up
more closely than current guidelines indicate. The current
literature suggests that more attention must be paid to pa-
tients with concomitant CAD and that the severity of aortic
valve calcification should be recognized as an important
predictor of outcome. Studying patients with these charac-
teristics and identifying any other pertinent predictors
unique to the veteran population will be an important next
step, and modifying the existing guidelines for more vulner-
able patients and involving both cardiologists and cardiac
surgeons early on in these cases will allow the management
of moderate AS to be tailored to individual patients’ needs.
Our study is subject to the limitations inherent in a retro-
spective review. Because our patient cohort was limited to
military veterans, nearly all of our patients were men. Con-
sequently, we cannot generalize our results to femalegery c June 2013
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cardiographic report to verify the severity of each patient’s
AS, we did not view the actual echocardiographic images to
verify the measurements. Thus, the parameters used in our
analyses were dependent on the image quality of the echo-
cardiogram and on the judgment of the interpreting cardiol-
ogist. Additionally, the concomitant presence of symptoms
of interest, including angina, syncope, and dyspnea, could
not be determined for our patients at the time of each echo-
cardiographic examination because of inconsistencies
within their medical records.
CONCLUSIONS
Our study is significant not only because it corroborates
emerging evidence that moderate AS is not a benign condi-
tion, but also because it focuses on the unique population of
military veterans, who have significant comorbidities and
risk factors. We found that moderate AS in this population
is associated with rapid progression and considerable mor-
tality. Therefore, the current practice guidelines for the
management of moderate AS may not be appropriate for
this group of patients. Further study of other prognostic fac-
tors unique to the veteran population is needed to improve
our ability to assess and manage this disease in an individ-
ualized manner.
Stephen N. Palmer, PhD, ELS, contributed to the editing of the
manuscript.
References
1. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD,
et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for
the management of patients with valvular heart disease: a report of the American
College of Cardiology/American Heart Association Task Force on Practice
Guidelines (Writing Committee to Revise the 1998 Guidelines for the Manage-
ment of Patients With Valvular Heart Disease): endorsed by the Society of Car-
diovascular Anesthesiologists, Society for Cardiovascular Angiography and
Interventions, and Society of Thoracic Surgeons. Circulation. 2008;118:
e523-661.
2. Lester SJ, Heilbron B, Gin K, Dodek A, Jue J. The natural history and rate of pro-
gression of aortic stenosis. Chest. 1998;113:1109-14.
3. Supino PG, Borer JS, Yin A, Dillingham E, McClymont W. The epidemiology of
valvular heart diseases: the problem is growing. Adv Cardiol. 2004;41:9-15.The Journal of Thoracic and Car4. Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, et al.
Guidelines on the management of valvular heart disease: The Task Force on
the Management of Valvular Heart Disease of the European Society of Cardiol-
ogy. Eur Heart J. 2007;28:230-68.
5. Ross J Jr, Braunwald E. Aortic stenosis. Circulation. 1968;38:61-7.
6. Carabello BA. Timing of valve replacement in aortic stenosis: moving closer to
perfection. Circulation. 1997;95:2241-3.
7. Carabello BA. Evaluation and management of patients with aortic stenosis.
Circulation. 2002;105:1746-50.
8. Carabello BA, Paulus WJ. Aortic stenosis. Lancet. 2009;373:956-66.
9. Otto CM. Valvular aortic stenosis: disease severity and timing of intervention.
J Am Coll Cardiol. 2006;47:2141-51.
10. Kennedy KD, Nishimura RA, Holmes DR Jr, Bailey KR. Natural history of mod-
erate aortic stenosis. J Am Coll Cardiol. 1991;17:313-9.
11. Otto CM. Aortic stenosis: even mild disease is significant. Eur Heart J. 2004;25:
185-7.
12. Otto CM, Burwash IG, Legget ME, Munt BI, Fujioka M, Healy NL, et al.
Prospective study of asymptomatic valvular aortic stenosis: clinical, echocar-
diographic, and exercise predictors of outcome. Circulation. 1997;95:
2262-70.
13. Rosenhek R, Klaar U, Schemper M, Scholten C, Heger M, Gabriel H, et al. Mild
and moderate aortic stenosis: natural history and risk stratification by echocardi-
ography. Eur Heart J. 2004;25:199-205.
14. Bahler RC, Desser DR, Finkelhor RS, Brener SJ, Youssefi M. Factors leading to
progression of valvular aortic stenosis. Am J Cardiol. 1999;84:1044-8.
15. Peter M, Hoffmann A, Parker C, Luscher T, Burckhardt D. Progression of aortic
stenosis: role of age and concomitant coronary artery disease. Chest. 1993;103:
1715-9.
16. Frank S, Johnson A, Ross J Jr. Natural history of valvular aortic stenosis.
Br Heart J. 1973;35:41-6.
17. Horstkotte D, Loogen F. The natural history of aortic valve stenosis. Eur Heart J.
1988;9 Suppl E:57-64.
18. Turina J, Hess O, Sepulcri F, Krayenbuehl HP. Spontaneous course of aortic valve
disease. Eur Heart J. 1987;8:471-83.
19. Wagner S, Selzer A. Patterns of progression of aortic stenosis: a longitudinal he-
modynamic study. Circulation. 1982;65:709-12.
20. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis,
disease progression, and treatment strategies. Circulation. 2005;111:3316-26.
21. Palta S, Pai AM, Gill KS, Pai RG. New insights into the progression of aortic
stenosis: implications for secondary prevention. Circulation. 2000;101:
2497-502.
22. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O’Brien KD. Characteriza-
tion of the early lesion of ‘degenerative’ valvular aortic stenosis: histological and
immunohistochemical studies. Circulation. 1994;90:844-53.
23. Rajamannan NM, Gersh B, Bonow RO. Calcific aortic stenosis: from bench
to the bedside—emerging clinical and cellular concepts. Heart. 2003;89:
801-5.
24. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-
valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl
J Med. 1999;341:142-7.
25. Witteman JC, Kok FJ, van Saase JL, ValkenburgHA. Aortic calcification as a pre-
dictor of cardiovascular mortality. Lancet. 1986;2:1120-2.diovascular Surgery c Volume 145, Number 6 1553
